Claims for Patent: 5,474,982

Summary for Patent: 5,474,982

Title:	PDGF analogs and methods of use
Abstract:	Proteins having substantially the same biological activity as PDGF are provided. In one aspect, a protein homodimer having two polypeptide chains is disclosed, each of the chains being a mosaic of amino acid sequences substantially identical to portions of the A- and B-chains of PDGF, the protein being chemotactic or mitogenic for fibroblasts. Therapeutic compositions comprising such proteins in combination with a physiologically acceptable carrier or diluent are also provided. Such therapeutic compositions may be used within methods for enhancing the wound-healing process in warm-blooded animals.
Inventor(s):	Murray; Mark J. (Seattle, WA), Kelly; James D. (Seattle, WA)
Assignee:	ZymoGenetics, Inc. (Seattle, WA)
Application Number:	08/273,779
Patent Claims:	1. An unglycosylated protein homodimer having two polypeptide chains, each of said chains being a mosaic of amino acid sequences substantially identical to portions of the A- or B-chains of PDGF, said protein being chemotactic or mitogenic for fibroblasts. 2. A therapeutic composition comprising an unglycosylated protein homodimer having two polypeptide chains, each of said chains being a mosaic of amino acid sequences substantially identical to portions of the A- or B- chains of PDGF, said protein being chemotactic or mitogenic for fibroblasts, and a physiologically acceptable carrier or diluent. 3. A method for enhancing the wound-healing process in warm-blooded animals, comprising administering to the animal a therapeutically effective amount of a composition comprising an unglycosylated protein homodimer having two polypeptide chains, each of said chains being a mosaic of amino acid sequences substantially identical to portions of the A- or B-chains of PDGF, said protein being chemotactic or mitogenic for fibroblasts, and a physiologically acceptable carrier. 4. The method of claim 3 wherein said carrier is selected from the group consisting of albumin, sterile water, polyethylene glycol and saline. 5. The method of claim 3 wherein said composition includes an adjuvant. 6. The method of claim 3 wherein said composition is administered topically. 7. The method of claim 3 wherein said composition is administered in a dose of from about 0.5 to about 10 .mu.g per cm.sup.2 of wound area. 8. The method of claim 3 wherein said composition includes an effective amount of basic fibroblast growth factor. 9. The method of claim 8 wherein the protein homodimer and the fibroblast growth factor are present in a ratio of from approximately 1 to 0.4, to 10 to 0.4, respectively. 10. The method of claim 3 wherein said warm-blooded animal is a diabetic animal.

Details for Patent 5,474,982

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2012-12-12